Eric White, Phd, Hcld(Abb) Email & Phone Number

Waltham, Massachusetts, United States

Consulting services for CLIA labs navigating LDT and FDA regulatory requirements for molecular diagnostic assay design, validation and submission for both CLIA and FDA testing requirements. I have extensive experience in NGS R&D and clinical assay development and test launch in a lab which had accreditation by CLIA, CAP, NYCLEP, and ISO15189.

Watertown, Massachusetts, United States

I was retained by Veracyte for three months following the acquisition of C2i Genomics to facilitate the closure of the C2i Genomics Watertown, MA lab and transfer of materials to Veracyte.

Watertown, Massachusetts, United States

I was responsible for all aspects of clinical and R&D operations of the C2i Genomics lab in Watertown, MA until C2i Genomics was acquired by Veracyte in Feb 2024. I am staying for 3 months (until May 2nd) with Veracyte to aid in the acquisition transition.

Cambridge, Ma

Site director of the C2i Genomics CLIA/CAP genetic diagnostic lab for cancer minimal residual disease and rare genetic disease testing. C2i Genomics purchased QNA Dx from Q-State Biosciences.

Cambridge, Massachusetts, United States

General manager and technical supervisor of QnA Dx, a subsidiary of Q-State Biosciences (Now Quiver Biosciences). QnA Dx was a CLIA and NYS CLEP certified and ISO 15189 accredited clinical genetics testing lab specializing in rare genetic disease. Responsible for all aspects of test R&D, validation, launch and clinical testing and reporting. Reports include R&D, laboratory testing personnel manager, clinical reporting medical director, software/bioinformatics, LIMS and client services. Launched CLIA tests include whole exome and genome sequencing and a genetic test for patient stratification for a Phase 2 FDA trial for dry age-related macular disease for a client biotech company which business I brought to Q-State Biosciences. Performed R&D for clinical tests for mRNA rare disease diagnostic sequencing and a cell-based assay for multiple myeloma drug sensitivity. Additionally, I was co-PI on an SBIR funded grant for development of antisense oligonucleotides for gene therapy for nervous system diseases, the main scientific focus of Q-State Biosciences.

Relaunch of Claritas Genomics clinical assays under the new company QnA Dx, a subsidiary of Q-State Biosciences that purchased Claritas Genomics. My role was continuation as R&D Director and technical operations. I was hired by WuXi NextCODE which was a significant investor of Claritas Genomics and remained associated with QnA Dx through clinical reporting software interests. This ended up being a temporary position as WuXi pulled out of the partnership and I moved onto QnA Dx which was a subsidiary of Q-State Biosciences.

Cambridge, Ma

R&D Director for Claritas Genomics, a spin-off from Boston Children's Hospital, for diagnosis of pediatric inherited disease. Claritas Genomics relaunched as QNADx in February 2018.• Director of the R&D group to design and validate genetic tests for pediatric inherited diseasediagnosis in a CLIA/ISO 15189 accredited clinical laboratory.• Evaluation of genomics technologies including Oxford Nanopore, Pacific Biosciences, Beijing Genomicsand BioRad ddPCR.• Launched the Claritas Clinical Exome. The exome is a dual platform next-generation sequencing testcomprised of an Illumina clinical research exome and Proton AmpliSeq Exome that orthogonally confirmsnearly 95% of variants and increases exome sensitivity compared to either platform alone.• Developed protocols for DNA extraction from blood, urine, saliva and whole tissue samples.• Developed protocols for highly sensitive mitochondrial DNA sequencing.• Utilized RNAseq for digital gene expression.• Validated and launched a custom 1M probe exon resolution microarray for CNV analysis.• Wrote white paper for Autogen showing excellent NGS results from their new DNA extraction instrument.• Investigated leukemia minimal residual disease testing by NGS assay.

Lab Development & OperationsLab director for the Claritas Genomics and ThermoFisher joint program to sequence >20,000 exomes for the VA Million Veteran Program.The Enterprise Solutions Group within Thermo Fisher Scientific was a global provider of end-to-end solutions for establishing Genomic Medicine Infrastructure at the population-scale, with a global base of customers at the level of national governments.

Ion Torrent, Inc. (Life Technologies) • Optimization of DNA library construction, emPCR conditions and reagents for Ion Torrent next-generation semiconductor sequencing PGM and Proton platforms. • Inventor of the Ion Sphere Quality Control Kit assay for inexpensive quantitation of templated sequencing beads utilizing Invitrogen’s (Life Technologies) Qubit 2.0 Fluorometer.• Inventor of Ion Torrent DNA Fragment library adaptors.Applied Biosystems, Inc. (Life Technologies) • Optimization of DNA library construction for the SOLiD next-generation sequencing platform. • Inventor of an enzymatic end-repair method for DNA sheared by sonication.• Customer site visitation and protocol transfer of new library constructionprotocols to early access customers.

U.S. Genomics, Inc., Woburn, MA Senior Scientist 10/2005-4/2010U.S. Genomics was a single molecule detection based company that utilizes a proprietary sample preparation system and confocal microscopy to map fluorescently tagged DNA molecules stretched to contour length in microfluidic flow. The technology is applicable to microbial detection in both the biodefense and human clinical diagnostics industries.• Designed, constructed and validated first and second generation Digital DNA™ a modular recombinant bacterial artificial chromosome series, for a highly multiplexed analyte detection system based on single-molecule detection of sandwich immunoassays.• Group leader of a team of 7 research associates to leverage USGs core Direct Linear Analysis™ single-molecule microbe identification technology for human diagnostic applications including directing multiple blind tests for a large publicly traded diagnostics company. In the process we built a database for identification of ~250 bacterial strains• Led DLA human diagnostics applications group to validate DLA for clinical diagnostics strain typing by direct comparison of DLA with pulsed-field gel electrophoresis restriction mapping of S. aureus strains obtained from a local hospital microbiology laboratory.• Gave multiple presentations both internally and externally for private and government funding partners, scientific review boards and academic conferences.• Biosafety Officer responsible for cataloging all biological agents and recombinant DNA molecules as well as actively monitoring their proper use and disposal.

Yale University, New Haven, CT Postdoctoral Fellow 2/2002-10/2005Department of Molecular, Cellular and Developmental BiologyAdvisor: Michael Snyder, Ph.D.• Utilized an “in house” produced genomic DNA microarray to map DNA replication timing and transcription along Human chromosome 22 in multiple cell types.• Initiated a large-scale genomics/proteomics project to express and identify transcription factors involved in neurogenesis in murine embryonic stem (mES) cells. Human and mouse transcription factors were cloned into a high throughput recombination dependent shuttle system and expressed and purified as protein transduction domain fusion proteins in baculovirus infected insect cells or shuttled into lentiviral vectors for viral infection and stable integration and expression in mES cells.Postdoctoral Grants and Fellowships:Ruth L. Kirschstein Individual National Research Service Award, 2003-2005National Human Genome Research Institute: NIH HG002715NIH Training grant awarded to Department of Pathology, 2002-2003Yale University: NIH DK07756.

Phd, Microbiology And Molecular Genetics

• Studied meiotic recombination and chromosome segregation in the yeast Saccharomyces cerevisiae in the laboratory of Dr. David Kaback. •.

Bs, Biology